Biosimilar Benefits to Patients, Health Care Professionals and the U.S. Market
Home / Biosimilar Benefits to Patients, Health Care Professionals and the U.S. Market
Monday June 24, 2019
Dr. Sameer Awsare, Internal Medicine Physician and Associate Executive Director at Kaiser Permanente Medical Group, sat down with the Biosimilars Council to talk about biosimilars, their benefits and the hurdles to adoption in the United States.
Dr. Awsare works closely with patients who are directly impacted by the promise of biosimilars. His knowledge of the industry and work with Kaiser Permanente – a leader driving the adoption of biosimilars – gives him a unique perspective on this important issue.
Watch and learn more about these important medicines, including:
What a biosimilar is.
The safety studies completed to demonstrate that switching between a brand biologic and biosimilar is safe.
How stakeholders can increase biosimilars uptake in the United States.
Dr. Sameer Awsare, Internal Medicine Physician, Associate Executive Director, Kaiser Permanente Medical Group, answers the following questions:
What is a biosimilar?
Are biosimilars safe?
What are the hurdles to biosimilar adoption in the United States?
Will increased biosimilar use benefit the United States healthcare system?
Watch the video for his answers and view the Biosimilars Council Handbook for more information.
About AAM
AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 22 percent of total drug spending.
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at www.biosimilarscouncil.org.
The Council is involved in a number of events that focus on advancing biosimilars in the United States. Click on one below to learn more:
October 21–23, 2024 | Rockville, MD
GRx+Biosims™ 2024 is the leading regulatory science and policy event for the U.S. generics and biosimilars industry. Access the most recent information straight from experts at the Food and Drug Administration, grasp the latest policies shaping the industry, and acquire valuable insights to propel your professional development.
